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Chronic abdominal pain is a debilitating
symptom of inflammatory bowel disease
(IBD): a chronic inflammatory condi-
tion of the gastrointestinal tract, which
includes Crohn’s disease (CD) and ulcer-
ative colitis (UC), and is characterized
by periods of inflammation and remis-
sion. During inflammation, pain is often
present due to the activation of affer-
ent nerve endings in the gut by inflam-
matory mediators (Beyak and Vanner,
2005). Importantly, pain associated with
IBD often persists after inflammation has
resolved, based on clinical and endoscopic
examination, and is often “referred” from
the gut to cutaneous or other visceral
regions (Minderhoud et al., 2004). Based
on what we know about pain process-
ing circuits, this suggests the source of
chronic and referred pain lies within the
central nervous system (CNS). These clin-
ical observations are supported by work
in animal models of visceral inflammation
that have provided behavioral, anatomi-
cal, molecular, and physiological evidence
to implicate spinal circuits in the devel-
opment of altered pain responses in IBD
(Farrell et al., 2014). In spite of this
evidence, little is known about the pre-
cise mechanisms of chronic pain devel-
opment and maintenance in IBD. This
lack of understanding severely limits cur-
rent therapeutic approaches for IBD pain
management.
PAIN MANAGEMENT IN IBD
Abdominal pain is a common symptom
of IBD, with up to 70% of patients pre-
senting with pain during disease onset,
or during periods of relapse (Wagtmans
et al., 1998). Pain is an indicator of inflam-
mation, and in the case of IBD, occurs in
response to the sensitization of intesti-
nal sensory neurons by inflammatory
cytokines. Importantly, inflammation
does not appear to be the sole cause of pain
in IBD, as 30–50% of patients in clinical
remission (i.e., no detectable inflamma-
tion in the gut) continue to experience
severe abdominal pain (Minderhoud
et al., 2004; Farrokhyar et al., 2006;
Siegel and MacDermott, 2009). The lack
of effective pain management for this
patient cohort is problematic in its own
right, but is also associated with signif-
icantly decreased health-related quality
of life scores, increased stress, anxiety,
and depression (Farrokhyar et al., 2006;
Schirbel et al., 2010). As a consequence,
a significant number of IBD patients
are chronically treated with narcotics
(Edwards et al., 2001; Cross et al., 2005;
Makharia, 2011). Unfortunately, long-
term narcotic use gives rise to a range of
side effects in IBD patients, such as nau-
sea, reduced gastrointestinal motility, and
narcotic bowel syndrome; i.e., increased
abdominal pain despite escalating narcotic
use. These detrimental effects worsen with
continued drug use (Grunkemeier et al.,
2007), yet the use of narcotics persists,
especially for IBD patients during hos-
pitalization and surgery associated with
relapse (Lian et al., 2010; Long et al., 2012).
These issues are compounded by the lack
of alternative pain management thera-
pies, as analgesics such as non-steroidal
anti-inflammatory drugs (NSAIDS),
including selective COX-2 inhibitors, are
linked to disease exacerbation (Bielefeldt
et al., 2009; Srinath et al., 2012). Given
the lack of options and efficacy issues with
current pharmaceutics, it is not surprising
that narcotic addiction is a major problem
in IBD. Rates of narcotic addiction are over
5% in Crohn’s patients and 2.7% overall
in IBD patients (Edwards et al., 2001),
with the risk increased by 8-fold in those
patients with concurrent psychiatric disor-
ders, including depression, anxiety, sexual,
emotional and physical abuse and sub-
stance abuse (Edwards et al., 2001; Hanson
et al., 2009). Thus, there is critical need for
new approaches and therapies for IBD
pain management. However, before new
therapeutics can be designed, the mech-
anisms responsible for the development
and maintenance of chronic abdominal
pain in IBD must be understood.
SENSORY TRANSMISSION IN THE
GASTROINTESTINAL TRACT
The gastrointestinal tract is unique as its
function is regulated by both intrinsic
and extrinsic components of the auto-
nomic nervous system. Intrinsic innerva-
tion is controlled by the enteric nervous
system (ENS), which consists of connect-
ing nerve plexuses that run between the
muscular layers and the submucosa of
the gut wall. The ENS controls gastroin-
testinal motility, secretion and absorption,
which are all essential for gut function, but
plays no major role in pain transmission
(Blackshaw et al., 2007).
The extrinsic innervation of the
gastrointestinal tract includes efferent
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parasympathetic and sympathetic auto-
nomic pathways that are involved in the
modulation of ENS activity. There are
also extrinsic sensory afferents that convey
information, including (but not exclu-
sive to) noxious (potentially painful) and
innocuous sensations, to the spinal cord
and brainstem. Brookes et al. have com-
piled a comprehensive review of extrinsic
sensory afferent types that innervate the
gut wall (Brookes et al., 2013). Sensory
afferents convey signals (including nox-
ious signals that cause pain) from the
lower gastrointestinal tract to the CNS
via two major nerve trunks, the splanch-
nic and pelvic nerves (Gebhart, 2000;
Blackshaw et al., 2007). These nerves
enter the CNS via the spinal cord dor-
sal horn, where sensory information is
subject to extensive modulation via local
interneuron networks and descending
influences (Melzack and Wall, 1965).
Finally, signals from the gut ascend to
the cortex via several pathways, includ-
ing the spinothalamic, spinoreticular and
spinomesencephalic tracts, where percep-
tion can occur (Craig, 2002; Jones et al.,
2006).
ALTERED NERVOUS SYSTEM
SIGNALING IN IBD-RELATED PAIN
There is a growing body of evidence from
animal studies, suggesting that a dysfunc-
tion of the nervous system plays a role in
the development of a chronic pain state in
IBD (Willis and Westlund, 1997; Gebhart,
1999; Hughes et al., 2009). Most research
on the neural mechanisms responsible for
pain in IBD has focused on the peripheral
nervous system, where strong evidence
of hyperexcitability in afferent nerves has
been documented. For example, in ani-
mal models of chemically induced colitis,
hypersensitivity of mechanosensitive sen-
sory afferents following inflammation has
been demonstrated, with reduced thresh-
olds for activation and increased frequen-
cies of action potential discharge reported
(Hughes et al., 2009; Feng et al., 2012).
Importantly, this hypersensitivity is sus-
tained following recovery from inflamma-
tion, whichmay be a contributing factor in
the development of chronic pain (Hughes
et al., 2009; Feng et al., 2012).
Other work has shown that colonic
inflammation can result in increased
behavioral responses to mechanical
distension and intraluminal adminis-
tration of capsaicin into the colon, and
that this hypersensitivity can be reversed
by antagonism of TRPV1 ion channels,
implicating TRPV1 expression in the
development of peripheral hyperalgesia
(Miranda et al., 2007). Taken together,
these data indicate that after colonic
inflammation, sensory afferents can
become hypersensitive to both mechan-
ical and chemical stimulation, and this can
be attributed, at least in part, to changes
in the expression of ion channels within
sensory afferents.
Although the evidence for peripheral
contributions to colonic hypersensitivity is
strong, the existence of referred pain in
IBD patients and in animal models of coli-
tis suggests the CNS, particularly the spinal
cord dorsal horn, is implicated in the
development of abnormal pain, as referred
pain cannot be explained by hypersensi-
tive colon afferents alone (Bernstein et al.,
1996). Referred pain is a common seque-
lae of visceral pain, in which diffuse,
poorly localized pain from the viscera
“referred” to other areas: most often to
the skin (Cervero and Laird, 1999). For
IBD, pain is often referred to the mid-
lower back, abdomen, and legs (Ritchie,
1973; Ness et al., 1990; Accarino et al.,
1995; Bernstein et al., 1996) and, not sur-
prisingly, is a source of great discomfort.
It is thought that referred pain occurs
when there is overlap between visceral and
somatic pathways within the CNS (Traub,
2000). The region of the CNS where this
cross over is most likely to occur is within
the spinal cord dorsal horn, as the dor-
sal horn receives inputs from skin, joints
and muscle as well as from the viscera
(Almeida et al., 2004).
Evidence that the CNS is involved in
the processing of inflammation-induced
visceral pain has been demonstrated in
animal models at behavioral, anatomi-
cal, molecular, and physiological levels
of analysis (Farrell et al., 2014). Briefly,
it has been shown that animals develop
referred hypersensitivity of the hind paw
and abdomen following colitis (Lamb
et al., 2006), and that this sensitivity
remains after the resolution of inflamma-
tion (Eijkelkamp et al., 2009). Likewise,
colitis results in increased dorsal horn
expression of markers of neural activa-
tion (cFos and pERK) following distension
(Traub and Murphy, 2002; Harrington
et al., 2012), as well as neuropeptides com-
monly linked with pain signaling, such as
Substance P and CGRP (Sun and Luo,
2004). Finally, the excitability of spinal
dorsal horn neurons has been shown to
increase following colitis, with extracellu-
lar recordings demonstrating a decrease in
action potential threshold and increases
in spontaneous neural activity (Al-Chaer
et al., 1997). We have previously presented
a systematic review outlining the evidence
for altered CNS activity following gas-
trointestinal inflammation (Farrell et al.,
2014).
Magnetic resonance imaging studies
have also demonstrated changes in the
structure and functional activation of
cortical and subcortical regions in IBD
patients compared with healthy controls.
Using fMRI, patients with IBDwere shown
to have differing patterns of cortical activa-
tion and deactivation in response to nox-
ious rectal balloon distension (Bernstein
et al., 2002). Likewise, CD patients exhibit
altered gray matter volumes in corti-
cal (frontal and anterior midcingulate
corticies) and subcortical regions that
are associated with emotion, cognition,
and nociception (Agostini et al., 2013).
Therefore, there is evidence for both spinal
and supra-spinal alterations as a conse-
quence of chronic pain in IBD.
FUTURE ADVANCES IN IBD PAIN
MANAGEMENT
The presence of chronic pain in IBD
patients represents a major health bur-
den, as it can impact significantly on
the quality of life and mental health
of long-term sufferers. Current pain
management strategies are not optimal:
often ineffective and associated with a
number of detrimental off-target effects
(Edwards et al., 2001; Hanson et al.,
2009; Siegel and MacDermott, 2009;
Srinath et al., 2012). Recent studies have
demonstrated that targeting specific CNS
pathways could alleviate visceral pain
in animal models. For instance, tar-
geting of central N-methyl-D-aspartate
(NMDA) receptors is of particular inter-
est, as there is strong evidence for spinal
NMDA receptor-dependent neurotrans-
mission underling the development of
central sensitization (Haley et al., 1990;
Ren et al., 1992). In models of colonic
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inflammation, microinjection of the
NMDA receptor antagonist DL-2-amino-
5-phosphonovaleric acid (APV) into the
rostral ventromedial medulla (RVM) was
shown to attenuate exaggerated behavioral
responses to colon distension. This atten-
uation was not observed for injections
outside the RVM (Coutinho et al., 1998).
Since spinal nociceptive transmission is
subject to modulation from supraspinal
sites such as the RVM, this demonstrates
that visceral hyperalgesia can be influ-
enced by NMDA-dependent descending
pain modulation. Likewise, cross-organ
sensitization between the inflamed colon
and the urethra was reversed by intrathe-
cal injection of APV, and by antagonism
NR2B: a subunit of the NMDA recep-
tor, using Co-101244 (Peng et al., 2009).
Therefore, direct antagonism of spinal
NMDA receptors, specifically the NR2B
subunit, can attenuate central sensitization
caused by inflammation of the colon.
Another potential candidate recently
investigated for visceral pain management
is the nociceptive ion channel TPVR1.
TRPV1 channels are activated by heat (>
43◦) and capsasin (Christoph et al., 2006)
and are expressed in up to 80% of visceral
afferents (vs. less than one third in somatic
afferents) (Robinson and Gebhart, 2008).
This makes these channels an appeal-
ing pharmacological target. Silencing of
TRPV1 in the CNS using intrathecal injec-
tion of TRPV1-specific siRNA 4 days prior
to intrarectal capsaicin administration was
shown to reduce capsasin-induced spon-
taneous pain behaviors in rats (Christoph
et al., 2006). Importantly, in models of
neuropathic pain, TRPV1-specific siRNA
analgesia could be maintained for 4–5
days (Christoph et al., 2006). Interestingly,
the siRNA used, VsiR1, is directed against
a segment of TRPV1 mRNA that is
conserved in mouse, rat and human,
suggesting this approach may be easily
translatable into humans.
Although new CNS targets for manag-
ing chronic visceral pain are emerging, the
blood brain barrier represents a continual
obstacle in the development of new thera-
peutics. The blood brain barrier presents
physical, transport and metabolic barri-
ers that can be modulated and regulated
under both normal and pathological states
(Abbott et al., 2010). Direct intrathecal
injection of therapeutics is the most direct
way to bypass these barriers, however, it is
by far the least practical solution in a clin-
ical setting. Importantly, recent advances
in nanoparticle carrier technologies may
allow better targeting of CNS pathways
involved in visceral pain through site-
directed drug delivery and enhanced pene-
tration of the blood brain barrier (Hua and
Wu, 2013).
In summary, visceral pain in chronic
inflammatory diseases is poorly under-
stood and current therapeutic strategies
are limited. Further research is required
to improve our knowledge of the events
leading to the development chronic vis-
ceral pain. In addition, the discovery of
improved CNS targets for pain manage-
ment along with improved methods for
drug delivery, are urgently required for the
management IBD patients with chronic
pain.
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